-SEC Filing
Immuneering Announces Initial Phase 1 Pharmacokinetic, Pharmacodynamic And Safety Data For IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
Data presented at AACR Annual Meeting support IMM-1-104's potential to address a broad population of patients with RAS mutant tumors
IMM-1-104 well tolerated with no dose limiting toxicities (DLTs) or serious